Although these negative results may lead us to reconsider the validity of the amyloid hypothesis, the results of current clinical trials of BACE-1 inhibitors in asymptomatic individuals at risk to develop AD or with prodromal AD are still to be seen.19 Here, BACE1 is linked to Alzheimer disease.